Ascendis Pharma ASND buyback news

Opinion · Devil's advocate

Fact-check-o-meter

Ascendis messaging mostly matches its filings, but the combo data and the profit headline need context

Ascendis's releases are largely in line with its interim report and 20-F, and the company is profitable with no going-concern language. The gaps are in emphasis: a one-time voucher sale drives the headline operating margin, recent releases drop the word 'accelerated' from YUVIWEL's U.S. approval, and the 'tripling of efficacy' claim for the combination rests on a 21-child open-label trial with no concurrent control. On Aug. 31, 2026 Ascendis filed a 6-K saying it had entered into a binding term sheet to settle all litigation with BioMarin, including the U.S. ITC case tried in April 2026, with a definitive agreement still to come.

1. Press release vs filing · weight low

   Q2 operating margin includes a one-time voucher sale

   The company said: "Operating profit for the second quarter of 2026 totaled €220 million, reflecting a margin of 65%. On a non-IFRS basis, operating profit was €92 million*, reflecting a margin of 27%*." source

   The record says: The interim report says the PRV sale closed in the second quarter and "The income from sale of the PRV, net of transaction costs was € 158.1 million and is presented as other operating income". It is also "included within cash flows from operating activities in the statements of cash flows". source

   Our view: The release does show the non-IFRS figure next to the IFRS one, so nothing is hidden. Still, the 65% margin and the first-half operating cash flow both carry a voucher sale that cannot repeat, and the 27% non-IFRS margin is the better guide to the run rate.

2. Press release vs filing · weight medium

   Recent releases drop 'accelerated' from YUVIWEL's U.S. approval

   The company said: "Making YUVIWEL available in select International Markets countries through early access programs using U.S. FDA approval." source

   The record says: The February approval report states the drug was approved "under the FDA's Accelerated Approval Program" and that "Continued approval for this indication, which was based on an improvement in annualized growth velocity, may be contingent upon verification and description of clinical benefit in confirmatory trial(s)." The interim report repeats: "In February 2026, we received accelerated approval of YUVIWEL". source

   Our view: The August results release and the August 6 program update describe YUVIWEL's FDA status without the word accelerated. The approval rests on growth velocity, a surrogate, so U.S. revenue depends on confirmatory data the later releases do not discuss.

3. Science · weight medium

   'Tripling of efficacy' comes from an open-label, single-arm phase 2

   The company said: "sustained increases in ACH-specific height Z-score, indicating a tripling of efficacy compared to TransCon CNP monotherapy." source

   The record says: The release itself calls COACH "an ongoing prospective Phase 2 open-label trial" with cohorts of "N=12" and "N=9". The ClinicalTrials.gov record lists a single-group design with no masking, an actual enrollment of 22, and a primary endpoint of growth velocity at week 52 measured as "cm per year, compared to navepegritide alone". source

   Our view: With no concurrent control arm, the comparison to monotherapy is against other trials, and the treatment-experienced cohort is small. The registry's enrollment of 22 also differs from the 21 children in the release. The planned phase 3 is where the 'tripling' claim gets a real test.

4. Legal and disclosure record · weight medium

   BioMarin patent litigation, including the U.S. ITC case, is covered by an Aug. 31 binding term sheet to settle

   The record says: The interim report says BioMarin filed "a complaint filed with the U.S. International Trade Commission ("ITC") related to alleged infringement of U.S. Reissue Patent No. 48,267. Trial in the ITC took place this April 2026." Ascendis's own suit in the U.S. Northern District of California "has been stayed in view of the pending ITC proceedings." The European '863 patent was revoked on October 16, 2025 and the UPC case dismissed. A 6-K filed on Aug. 31, 2026, after the interim report, says Ascendis "entered into a binding term sheet for a global settlement and license agreement with BioMarin" and that the term sheet "provides the terms and conditions upon which the companies agree to resolve all litigation and disputes between the companies". Ascendis would pay royalties of 20% in the United States and 18% in the European Union, South Korea and Brazil on net sales of navepegritide-related products through May 20, 2030, and each side would dismiss its proceedings against the other. The 6-K refers to an anticipated definitive agreement. A 6-K filed on Aug. 31, 2026, after the interim report, says Ascendis "entered into a binding term sheet for a global settlement and license agreement with BioMarin" and that the term sheet "provides the terms and conditions upon which the companies agree to resolve all litigation and disputes between the companies". Ascendis would pay royalties of 20% in the United States and 18% in the European Union, South Korea and Brazil on net sales of navepegritide-related products through May 20, 2030, and each side would dismiss its proceedings against the other. The 6-K refers to an anticipated definitive agreement. A 6-K filed on Aug. 31, 2026, after the interim report, says Ascendis "entered into a binding term sheet for a global settlement and license agreement with BioMarin" and that the term sheet "provides the terms and conditions upon which the companies agree to resolve all litigation and disputes between the companies". Ascendis would pay royalties of 20% in the United States and 18% in the European Union, South Korea and Brazil on net sales of navepegritide-related products through May 20, 2030, and each side would dismiss its proceedings against the other. The 6-K refers to an anticipated definitive agreement. No securities litigation or enforcement action is disclosed. source

   Our view: The August results release and the October CHMP release mention litigation only in generic forward-looking language and do not mention the term sheet. The interim report says Ascendis believes BioMarin's claims lack merit, while the later 6-K describes a settlement with royalty payments, so the definitive agreement and its final terms are the facts to follow.

This is opinion. We compare the company's own announcements with its filings and the scientific record, and link every source. It is not an allegation of wrongdoing and not investment or legal advice. Legal items list only matters disclosed in filings or by courts and regulators. Checked Oct 23, 2026. Companies can respond through our right of reply.